Specifically, our findings propose a novel therapeutic direction where EZH2 inhibition regulates cysteine metabolism and potentially mitigates sorafenib resistance, thus enhancing the induction of ferroptosis in HCC. Here, EZH2 is linked to hepatocellular carcinoma.